# High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

> **NCT01237951** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 75 (actual)

## Conditions studied

- Myeloma

## Interventions

- **DRUG:** Palifermin
- **DRUG:** Dexamethasone
- **DRUG:** Gemcitabine
- **DRUG:** Busulfan
- **DRUG:** Melphalan
- **PROCEDURE:** Stem Cell Transplant
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT01237951
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-08
- **Primary completion:** 2017-09-20
- **Final completion:** 2017-09-20
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2020-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01237951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01237951, "High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01237951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*